|
1.Mauer,A.M.:Hodgkin disease in:Williams hematology,5th edn.,pp.1995:1004-1016.
2.Haung,M.E.,Ye,Y.C.:Use of all trans retinoic acid in the treatment of acute promyelocytic leukemia.Blood 1988;72:567-572.
3.Chen,G.Q.,Shen,Z.X.:Pharmacokinetics and efficacy of low-dose all-trans retinoid acid in the treatment of acute promyelocytic leukemia.Leukemia 1996;10:825-828.
4.Chen,Z.,Brand,N.J.:Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11:17)(q23;q21) in a patient with acute promyelocytic leukemia.J.Clin.Invest.1993;91:2260-2267.
5.Tsuda, H.Hara,H. S.:Toxicological study on antineoplaston A-10 and AS2-1 in cancer patient.The Krume medical J.1995;42:241-249.
6.Hoffman,F.A.:Micronutrient requirements of cancer patients.Cancer 1985;55:295-300.
7.Kochi M.,Ueda S.:Antitumor activity of sodium benzylideneascorbate. Progr. in Cancer Res. 1988;35:338-343.
8.Sakagami H.,Asano K.:Induction of tumor degeneration by sodium benzylideneascorbate. Anticancer Res. 1991;11:1533-1538.
9.Kuribabyashi N.,Sakagami T.:Induction of DNA fragmentation in human myelogenous leukemic cell lines by sodium 5,6-benzylidene-L-ascorbate and its related compounds.Anticancer Res. 1994;14:969-976.
10.Tauma S.,Shinokawa D.:Benzylideneascorbate induces apoptosis in L929 tumor cell.Biochem Biophys. Res. Commun.1993;194:29-35.
11.何紹奇：現代中醫內科學。中國醫藥科技出版社 1990: 536-539
12.曹炳章：中國醫學大成第一冊。中國中醫藥出版社 1997: 236-259 , 461-464.
13.東漢．張仲景:金匱教學資料。啟業書局 1984: 189-209.
14.張伯臾：中醫內科學。知音出版社 1992:402.
15.明代．張景岳:景岳全書。上海古籍出版社1990:475-482.
16.張伯臾：中醫內科學。知音出版社 1992:403.
17.東漢．張仲景:傷寒雜病論。志遠書局 1996:203.
18.王輝武：中醫百家薈萃。重慶出版社 1997:5.
19.王輝武：中醫百家薈萃。重慶出版社 1997:6.
20.唐代．孫思邈：千金要方上。上海古籍出版社1990:777-802.
21.明代．李時珍:本草綱目。上海古籍出版社1990:530.
22.Mazza, J.:Manual of clinical hematology.2nd edition.1995:p425
23.Chen Z., Wang Z.Y., Chen S.J.:Acute promyelocytic leukemia:Cellular and molecular basis of differentiation and apoptosis.Pharmacol. Ther.1997;76:141-149.
24.Barbui, T., Finazzi, G.:The impact of all-trans retinoid acid on the coagulopathy of acute promyelocytic leukemia.Blood 1998;91:3093-302.
25.Warrel,R.P.:Differentiation therapy of acute promyelocytic leukemia with tretinoin(all-trans retinoid acid).N.E.J.M.1991;324:1385-1393.
26.Bernard, J.:Acute promyelocytic leukemia:Result of treatment by daunorubicin.Blood 1973;41:489.
27.Bhagarthi,A.,Narayanan,E.:The effect of all-trans and 9-cis retinoid acid on the steady state level of HPV 16 E6/E7 mRNA and cell cyclin in cervical carcinoma cells.Life science 1998;63:565-573.
28.Hausen ,H.Z.:Molecular carcinogen 1988;1:147-150.
29.Hausen,H.Z.:Virology 1991;184:13.
30.Warrell, R.P.:Acute promyelocytic leukemia.N.E.J.M 1993;329:177.
31.Kuribayashi,N.,Sakagami,T.,Tanimoto,Y.:Induction of DNA fragmentation in human myelogenous leukemic cell lines by sodium 5,6-benzylidene-L-ascorbate and its related compounds.Anticancer Res. 1994;14:969-976.
32.Fujinaga,S.,Sakagami,H.:Possible role of hydrogen peroxide in apoptosis induction by ascorbic acid in human myelogenous leukemic cell lines.Showa. Univ J.Med.Sci.1994;6:135-144.
33.Sakagami,H.:The requirement for and mobilization of calcium during induction by sodium ascorbate and by hydrogen peroxide of cell death.Life Science 1996;58:1131-1138.
34.Sakagami,H.:Endonuclease activity and induction of DNA fragmentation in human myelogenous leukemic cell lines.Anticancer Res.1995;5:259-266.
35.Bram,S., Froussard,P., Guichard,M.:Vitamin C preferential toxicity for malignant melanoma cells.Nature 1980;284:629-631.
36.Scott,J.A., Kolodny,G.M.:Interaction of ionizing radiation and ascorbic acid on 3T3 mouse fibroblast.Int.J.Vit.Res. 1981;51:155-160.
37.L.Benade,T.Howerd.Synergistic killing of Ehrlich ascites carcinoma cells by ascorbate and 3-amino-1,2,4-triazole.Oncology 1984;108:160-162.
38.De Laurenzi,V., Melino,G.:Cell death by oxidative stress and ascorbic acid regeneration in human neuroectodermal cell line.Europ. J. Can. 1995;31:463-466.
39.Sakagami,H.,Asano,K.:Induction of tumor degeneration by sodium benzylideneascorbate.Anticancer Res. 1991;11:1533-1538.
40.Sakagami,H.,Takeda,M.:Effect of sodium benzylideneascorbate on chemically induced tumors in rats.Anticancer Res. 1993;13:65-72.
41.Cameron,E., Pauling,L.:Supplemental ascorbate in the supportive treatment of cancer:Prolongation of survival times in terminal human cancer.Proc. Natl. Sci .USA 1976;73:3685-3869.
42.Cameron,E., Pauling,L.:Supplemental ascorbate in the supportive treatment of cancer:Reevaluation of prolongation of survival times in terminal human cancer.Proc. Natl. Acad. Sci. USA 1976;75:4538-4542.
43.Moertel,C.G.,Fleming,T.R.:High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy.A randomized double-blind comparison.N. E. J. M. 1985;312:137-141.
44.Kochi, M.,Takeuchi,S.:Antitumor activity of benzaldehyde.Cancer Treat. Rep. 1980;64:21-23.
45.Kochi,M.,Ueda,S.: Antitumor activity of benzaldehyde derivative. Cancer Treat. Rep. 1985;69:533-537.
46.Kochi,M.,Ueda,S.: Antitumor activity of sodium benzylideneascorbate. Progr. in cancer res. and thera. 1988;35:338-343.
47.Tatsumura,T.,Tsujimoto,M.:4,6-O-benzylidene-D-glucopyrose in the treatment of solid malignant tumors,and extended phaseⅠstudy.Br. J.Cancer 1990;63:436-439.
48.Cameron,E.,Pauling, L.:supplemental ascorbate in supportive treatment of cancer:Prolongation of survival times in terminal human cancer.Pro. Natl. Acad. Sci.USA 1976;73:3685-3869.
49.Wittes,R.E.:Vitamin C and cancer.N.E.J.M. 1985;312:178-179.
50.Christian,M.:Ascorbic acid( vitamin C)improves the antineoplastic activity of doxorubicin,cisplatin,and paclitaxel in human breast carcinoma cell in vitro.Cancer letters 1996;103:183-189.
51.Gemba,M. ,Fakuishi,N.:Amelioration by ascorbic acid of cisplatin-induced injury in cultured renal epithelial cells.Contrib. Nephrol. 1991;95:138-142.
52.Chiang,C.D.,Song,E.J.:Ascorbic acid increases drug accumulation and reverses vincrinstine resistance of human non-small-cell lung-cancer cells.Biochem.J. 1994;301:759-764.
53.Gichner,T., Baedaev, S.A.:Effects of humic acids,para-aminobenzoic acid and ascorbic acid on the N-nitrosation of the carbamate insecticide propoxur and on the mutagenicity of nitrosopropoxur.Mutation. Res. 1990;229:37-41.
54.Khudoley,V.C.:Mutagenicity studies in Salmonella typhimurium on some carcinogenic N-nitramines in vitro and in the host-mediated assay in rats.Cancer Res. 1981;41:3205-3210.
55.Burzyski, S.R.:Antineoplaston:history of the research .Drugs Under and Exper. Clin. Res.1986;12:1-9.
56.Burzyski,S.R.:Antineoplaston:Biochemical defence against cancer.Physiol. Chem. Phys. 1976;8:275-279.
57.Tsuda,H.:The effect of antineoplaston,a new antitumor agent on malignant brain tumor.Krume Med. J. 1995;42:133-140
58.Tsuda,H.:Inhibitor effect of antineoplaston A-10 on breast cancer transplant to athymic mice and human hepatocellular carcinoma cell line.Krume Med. J. 1990;37:97-104.
59.Kumabe,T.,Tsuda,H.:Antineoplaton treatment for advanced hepatocellular carcinoma.Oncology 1998;5:1363-1367.
60.Tsuda,H.,Sugihara,S.:The inhibitory effect of the combination of antineoplaston A-10 injection with a small dose of cis-diamminedichloroplatinum on cell and tumor growth of hepatocellular carcinoma.Japanase J. of Cancer Res. 1992;83:527-531.
61.Badria,F., Mabed,M.:Immune modality potentiate of antineoplaston A-10 in breast cancer patient.Can. Let. 2000;157:57-63.
62.Samid,D.:Interferon in combination with antitumorigenic phenyl derivatives:potentiation of interferon alpha activity in-vitro.Br. J. Haematol. 1991;79:81-83.
63.Samid,D.,Shack,S.:Phenylacetate:A novel nontoxic inducer of tumor cell differentiation.Cancer Res. 1992;52:1988-1992.
64.Liau,MC.,Burzyski,SR.:Altered methylation complex isozymes as selective targes for cancer chemotherapy.Drugs Exp. Clin. Res. 1986;1:77-86.
65.Buchner, J.C.:Phase Ⅱ study of antineoplaston A10( NSC 648539) and AS2-1( NSC 620261) in patients with recurrent glioma.May. Clin. Pro. 1999;74:137-145.
66.Antineoplastons:request for phase Ⅱ trial in CNS malignancies. CTEP Lett 1992;10:10.
67.Stockhammer,G.,Samid,D.,Ram,Z.:Inhibition of proliferation and induction of differentiation in medulloblastoma- and astrocytoma-derived cell lines with phenylacetate. J.Neurosurg. 1995;83:672-681.
68.Ram,Z.,Samid,D.:Growth inhibition,tumor maturation,and extended survival in experimental brain tumors in rats treated with phenylacetate.Cancer Res. 1994;54:2923-2927.
69.Juszkiewicz,M.,Chodkowska,A.:The influence of antineoplaston A5 on particular subtype of central dopaminergic receptor.Drugs Under Exp. and Clin. Res.1995;21:153-156.
70.Lian, M.C., Lee, S.S.:Hypomethylation of nucleic acid:A key to the induction of terminal differentiation.Int. J. Exp. Chem . 1989; 2:187-199.
71.Green,S.:Antineoplaston.An unproved cancer therapy.J.A.M.A . 1992;267:2924-2928.
72.Samid,D.,Yeh,A.:Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate.Blood 1992;80:1576-1581.
73.Samid,D.,Shack,S.:Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate.J. Clin. Invest. 1993;91:2288-2295.
74.Samid,D.,Ram,Z.:Selective activity of phenylacetate against malignant gliomas:resemblance to fetal brain damages in phenylketouria.Cancer Res. 1993;54:891-895.
75.Weizsaecker,M.,Deen,D.F.:The 9L rat brain tumor:description and application of an animal model.J .Neurol .1981;224:183-192.
76.Ozawa, T., Lu, R. M.:Radiopontentiation of human brain tumor cells by sodium phenylacetate.Cancer Letters 1999;142:139-142.
77.Sporn, M.B.:Carcinogenesis and cancer:different perspectives on the same disease.Cancer Res. 1991;51:6215-6218.
78.Warrell,R.P.:Differentiation agents.In Devita VT Jr.,Hellman S,Rosenberg S.A.,editor.Cancer:priciples and practice of oncology.Volume 1.5th edition.Philadelphia:J.B.Lippincott 1997;483-490.
79.Lippman,S.M.,Benner, SE.:Cancer chemoprevention.J .Clin. Oncol. 1994;12:851-873.
80.Sporn,M.B.,Dunlop,NM.:Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs( retinoids): Fed.Proc. 1976; 35: 1332-1338.
81.Moon,R.C.,Mehta,RG.:Retinoids and cancer in experimental animals.In:Sporn MB,Robers AM,Goodman DS,editors.The retinoids:biology,chemistry and medicine.2nd edithion.New York:Raven Press. 1994:573-95.
82.Lotan,R.:Retinoids in cancer chemoprevention.FASEB J. 1996;10:1031-1039.
83.Lotan,R.:Effects of vitamin A and its analogs( retinoids) on normal and neoplastic cells.Biochim. Biophys. Acta. 1980;605:33-91.
84.Smith,M.A.,Parkison,DR.:Retinoids in cancer chemotherapy.J.Clin. Oncolo. 1992;10(5):839-864.
85.Sporn, M.B.,Robert, A.B.:The retinoids:biology,chemistry and medicine.2nd edition.New York:Raven Press. 1994.
86.Bollag,W.,Holdener, E.E.:Retinoids and cancer prevention and therapy.Ann. Oncol. 1992;3:513-526.
87.Blomhoff, R.,Green, M.H.:Transport and storage of vitamin a.Science 1990;250:399-404.
88.Blaner,W.S.,Olson,J.A.:Retinol and retinoic acid metabolism.In:Sporn MB,Robert AB,Goodman DS,editors.The retinoids:biology,chemistry and medicine.2nd edition.New york:Raven Press.1994:229-255.
89.Lippman,S.M.,Lee,J.S.:Chemoprevention of upper aerodigestive tract cancer.Head Neck 1990;12:5-20.
90.Hill, D.L.,Grubbs,C.J.:Retinoids and cancer prevention.Annu. Rev .Nutr. 1992;2:161-181.
91.Tang,G.,Russel, RM.:13-cis-retinoid acid is an endogenous compound in human serum.J .Lipid. Res .1990;30:175-182.
92.Heyman, R.A.,Mangelsdrof ,DJ.:9-cis-retinoic acid is a high affinity ligand for the retinoid X receptor.Cell 1992;68:397-406.
93.De Vries, N.,Pastorino, U.:Chemoprevention of second primary tumors in head and neck cancer in Europe.Eur. J .of Cancer 1994;30B:367-368.
94.Degos,L.,Dombert,H.:All-trans-retionic acid as a differentiating agent in the treatment of acute promyelocytic leukemia.Blood 1995;85:2643-2653.
95.Lippman,S.M.,Kavanagh,J.J.:13-cis-retinoic acid plus interferin alpha-2a:highly active systemic therapy for squamous cell carcinoma of the cervix.J. Natl. Cancer. Inst. 1992;84:241-245.
96.Lippman,S.M.,Parkison,D.R.: 13-cis-retinoic acid plus interferin alpha-2a:effective combination therapy for advanced squamous cell carcinoma of the skin.J. Natl. Cancer Inst. 1992;84:235-241.
97.Szark,C.E.,Grana,G.:Chemoprevention of cancer.Curr. Probl. Cancer 1994;18(1):6-79.
98.Miller,W. H.:The emerging role of retinoids and retinoid acid metabolism blocking agent in the treatment of cancer.Amer. Cancer Soci. 1998:1471-1482.
99.Muinidi,J.,Frankel,S.R.:Continuous treatment with all-trans retinoic acid causes a progressive decrease in plasma concentrations: implication for relapse and resistance in acute promyelocytic leukemia.Blood 1992;79:299-303.
100.Smets,G.:Liraoloe,an antitumor drug,modulates cytokeratin expression in the Dunning AT-6sq prostatic carcinoma through in situ accumulation of all-trans retinoic acid.Prostate 1995;27:29-40.
101.Achkar, C.C.,Bentel ,J.M.:Differences in the pharmacokinetic properties of orally administered all-trans retinoic acid and 9-cis-retinoic acid in the plasma of nude mice.Drug Metab. Dispos.Biol. Fate Chem. 1994;22(3):451-458.
102.Wouter,W.:Effect of liarozole,a new antitumoral compound,on retinoic-acid inhibition of cell growth and on retinoic acid metabolism in MCF-7 human breast cancer cells.Cancer Res.1992;52:2841-2846.
103.Van Heusden, J.,Borgers,M.:Liaroloe potentiates the all-trans retinoic acid-induced structural remodeling in human breast carcinoma MCF-7 cells in vitro.Eur. J Cancer Biol. 1996;71:89-98.
104.Hall,A.K.:Liarozole amplifies retinoid-induced apoptosis in human prostate cancer cell.Anticancer Drugs 1996;7:312-320.
105.廖明徵博士:聰明的抗癌藥。世茂出版社 1991:139-214.
106.Chapeker,M.S.:Effects of fibroblast and recombinant leukocyte interferons and double strand RNA on ppp(2’-5’) A synthesis and cell proliferation in human colon carcinoma cell in vitro.Cancer Res.1983;43:2683.
107.Bourgeade,M.F.:Induction of 2’,5’-oligoadenylate synthetase by retinoic acid in two transformed human cell lines.Cancer Res. 1984;44:5355-5360.
108.Testa, N.:Effect of endogenous and exogenous interferon on the differentiation on human monocyte cell line U937.Cancer Res. 1988;48:82-90.
109.Salzberg,S.:Interferon-independent activation of(2’-5’) oligoadenylate synthetase in Friend erythroleukemia cell variants exposed to HMBA.J. Cell Sci .1996;109:1517-1519.
110.De La Rosa, J.:Induction of interleukin 2 production but not methionine adenosyltransferase activity or S-adenosylmethionine turnover in Jurkat T-cells.Cancer Res. 1992;52:3361-3364.
111.Chiba, P. :S-adenosylmethionine metabolism in HL-60 cells:Effect of cell cycle and differentiation.Biochem Biophys Acta 1988;97:38-45.
112.Farid,Badria.:Potential utility of antineoplaston A-10 level in breast cancer.Cancer Letter 2000;155:67-70.
113.Liau,M.C.:Quantitate assay of plasma and urinary peptides antineoplaston therapy.Drugs Under Exp. Clin.Res. 1987;13:61-70.
114. Miwa,I.:Presence of three peptides in urinary kinin( substance Z)preparation.Life Sci. 1968;7:1339-1347.
115. Wollheim,E. :A humoral factor in the genesis of essential hypertension.Klin.Wochenscher 1971;49:426-433.
116.Liau, M.C.:Ribofalvin as a minor active anticancer component of antineoplaston A2 and A5.Intl. J.Tiss. React. 1990;120:19-26.
117.Liau,M.C.:Development of helper inducer to take part in the differentiation therapy of cancer.Pharm. J. 1999
118.Friend,C.:Depletion of sodim butyrate from the culture medium of Friend erythroleukemia cell undergoing differentiation.Cancer Res. 1987;47:378-350.
119.Weber,G.:Biochemical strategy of cancer cells and the design of chemotherapy:G.H.A Clows Memorial Lecture.Cancer Res. 1983;43:3466-3492
120.Dorota,S.P.:Cellular accumulation of antineoplaston AS21 in human hepatoma cell.Cancer Letter 1995;88:107─112.
121.Erard,F.:Inhibitors of cell division reversibly modify hemoglobin concentration in human erythroleukemia K562 cells.Blood 1981;58:1236-1239.
122. Stockhammer, G.:Inhibition of proliferation and induction of differentiation in medulloblastoma —and astrocytoma-derived cell lines with phenylacetate.J. Neurosurg. 1995;83:672-681.
123. Thibault,A.: A phase 2 and pharmacokinetic study of intravenous phenylacetate in patient with cancer.Cancer Res. 1994;54:1690-1694.
124.Kampalath,B.N.:Chemoprevention Antineoplaston A-10 of Benzo pyrene induced pulmonary neoplasia. Drugs Under Exp. and Clin.Research 1987;13:51-55.
125.Eriguchi,N.:Chemopreventive effect of Antineoplaston A-10 on urethane-induced pulmonary neoplasm in mice.J Jpn.Soc. Cancer Ther. 1988;23:1560-1565.
126.Burzyski,S.R.:Phase 2 clinical study of antineoplaston A5 injection. Drugs Under Exp. and Clin. Res. 1987;13:37-43.
127.Vyas,R.C.:Probing the pathobiology of response to all-trans retinoid acid in acute promyelocytic leukemia:premature chromsome condensation/fluorescence in situ hybridization analysis.Blood 1996;87:218.
128.Amisen,J.C.:Cell dysfunction and depletion in AIDS:The programmed cell death hypothesis.Immunol.Today 1991;12:102-105.
129.Hollowood ,D.K.:Reduced apoptosis cell death in follicular lymphoma.J. Pathol. 1991;163:337-342.
130.Buttke,T.M.:Oxidative stress as a mediator of apoptosis.Immuno. Today 1994;15:7-10.
131.Zamzami,N.:Reduction in mitochondril potential constitutes an early irreversible step of programmed lymphocye death in vivo.J .Exp. Med. 1995;181:1661-1672.
132.Vayssiere J.L.:Commitment to apoptosis is assosicated with changes in mitochondrial biogenesis and activity in all lines constitutionally immortalized with Simian Virus.Proc. Natl. Acad. Sci. USA 1994;91:11752-11756.
133.Zamami,N:Sequential reduction of mitochondrial trans membrane potential and generation of reactive oxygen species in early programmed cell death.J. Exp. Med. 1995;182:367-377.
134.Golstein,P.:Controlling cell death.Science 1997;275;1081-1082.
135.Papa,S.:Mitochondrial oxidative phosphorylation changes in the life span.Molecular aspects and physiopathological implication.Bioch. Biophys. Acta. 1996;1276:87-105.
136.Earnshaw,W.C.:Apoptosis lessons from in vitro system trend in cell.Biol. 1995;5:217-229.
137. Ferlini,C.:Sequence of metabolic change during X-ray induced apoptosis.Exp. Cell Res.1999;247:160-167.
138. Sakagmmi, H:Modulating factors of radical intensity and cytotoxic activity of ascorbate.Anticancer Res. 1997;17:3513-3520.
139.Carr,A.:Does vitamin C act as a pro-oxidant under physiological conditions?FASEB 1998;18:2503-2506.
140.Podmore,I.D.:Vitamin C exhibits pro-oxidant properties (letter).Nature(London) 1998;392:559.
141.Amano,Y.:Uncoupling of incorporation of ascorbic acid and apoptosis induction.Anticancer Res. 1998;18:2503-2506.
142.Ferenc,P.:Stimulation of the pentose phosphate pathway and glutathion level by dehydroascorbate,the oxidized form of vitamin C.FASEB. 2000;143:1352-1361.
143. Parolim,M.:The natural prooxidant activity of vitamin C.Life Science 1999;64:273-278.
144.Yanagisawa,S. F.:Endonuclease activiy and induction of DNA fragmentation in human myelogenous leukemic cell lines. Anticancer Res.1995;15:259-266.
145.Tanuma,S.:Multiple forms of nuclear deoxyribonucleas in rat thymocytes.Biochem Biophys. Res. Commun 1994;203:789-797.
146.Nikonova,L.S.:Properies of some nuclear nuclease of rat thymocytes and their changes in radiation induced apoptosis.Eur. J . Biochem. 1993;215:893-901.
|